Vaccine and Therapeutics Focus Flow Pharma is actively developing vaccine candidates targeting Ebola, Marburg, COVID-19 and oncology indications, presenting potential collaboration or co-development opportunities with organizations seeking novel vaccines or adjuvanted delivery platforms.

Patented Delivery Platform The FlowVax adjuvanted microsphere peptide platform represents a differentiated technology for vaccine and therapeutic delivery, suitable for partnerships, licensing, or contract development with biotech and pharma sponsors looking to enhance immunogenicity and targeted delivery.

Strategic Financing History Past equity financing indicates investor interest and potential for future funding rounds or strategic partnerships; consider engaging with Flow Pharma for early collaboration grants, milestone-based partnerships, or convertible financing discussions.

Small Team, Niche Focus With a lean team and specialized R&D in biomedicines, Flow Pharma may value externally resourced collaborations, CRO/CMO partnerships, and joint development agreements to accelerate programs while maintaining tight capital controls.

Geographic and Market Readiness Based in Solon, Ohio and targeting global infectious disease and cancer indications, Flow Pharma could benefit from U.S. translational funding, public-private partnerships, and strategic alliances with larger biopharma or contract manufacturing networks to scale impact and distribution.